A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
详细信息 查看全文
- 作者：Sun Min Lima ; b ; Byoung Chul Chob ; Sang-We Kimc ; Seok Yun Kangd ; Dae Seog Heoe ; Heung Tae Kimf ; Dae Ho Leec ; Dong-Wan Kime ; Minkyu Jungb ; Jin-Hyuk Choid ; Hyo Sup Shimg ; Jong Rak Choih ; Joo-Hang Kima ; b ; kim123@cha.ac.kr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Non-small-cell lung cancer ; Sorafenib ; Erlotinib
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：93
- 期：Complete
- 页码：1-8
- 全文大小：1302 K
文摘
- •
Targeting angiogenesis and EGFR pathway are important in non-small-cell lung cancer.
- •
We examine the efficacy and safety of sorafenib and erlotinib.
- •
Sorafenib combined with erlotinib is well-tolerated with manageable toxicity.
- •
Benefit in EGFR wild type patients warrant further investigation.